ClinicalTrials.gg

Program

AGA2118

A development code.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis, led by 2 companies.

Furthest: phase 2, since Aug 14, 20243 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Angitia Biopharmaceuticals21 open or runningphase 2since Aug 14, 2024Jan 11, 2022Dec 2026phase 2 · NCT06577935
Angitia10 open or runningphase 1since Jan 16, 2026Jan 16, 2026none ahead

Also a collaborator on its studies: angitia-australia-pty-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2022First study: phase 1 study in OsteoporosisNew to Angitia BiopharmaceuticalsAngitia Biopharmaceuticals · NCT05225857 · 90 enrolled · Australia
  2. Aug 14, 2024Phase 2 study in Osteoporosis, PostmenopausalAngitia Biopharmaceuticals · NCT06577935 · 379 enrolled · United States, Argentina, Poland and more
  3. Jan 16, 2026Angitia's first study: phase 1 study in Healthy ParticipantsNew to AngitiaAngitia · NCT07361354 · 28 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Osteoporosis, PostmenopausalAngitia Biopharmaceuticals · NCT06577935

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07361354Healthy Participants · United States1CompletedAngitiaSep 5, 202628
NCT06577935Osteoporosis, Postmenopausal · United States, Argentina, Poland and more2Active, not recruitingAngitia BiopharmaceuticalsDec 2026379
NCT05225857Osteoporosis · Australia1CompletedAngitia BiopharmaceuticalsJan 13, 202490

How it is read

Names in the registry

  • “AGA2118”, 3 entries

Codes read as this program: AGA2118.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.